Journal of the Korea Academia-Industrial cooperation Society (한국산학기술학회논문지)

The Korea Academia-Industrial cooperation Society (한국산학기술학회)
권호 표지
DOI QR코드

DOI QR Code

Effects on the Risk of Cardiovascular Disease in Breast Cancer Patients Received Postoperative Adjuvant Anticancer Therapy

유방암 환자의 수술 후 보조적 항암 치료가 심혈관질환 위험에 미치는 영향

  • Yu, Mi-Seon (Department of Pharmacy, Chungnam National University Hospital) ;
  • Lee, Tae-Yong (Department of Preventive Medicine and Public Health, School of Medicine, Chungnam National University)
  • 유미선 (충남대학교병원 약제부) ;
  • 이태용 (충남대학교 의학전문대학원 예방의학교실)
  • Received : 2014.01.17
  • Accepted : 2014.05.08
  • Published : 2014.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

To find the risk of cardiovascular disease for breast cancer patients received postoperative adjuvant anticancer therapy, this study was investigated the change of serum lipid profile (total cholesterol and trigyiceride) and the 10 year risk score of ischemic heart disease. Medical data of 432 breast cancer patients diagnosed at the breast cancer center in an university hospital from January, 2003 to December, 2006 were collected and analysed. The results showed that the levels of total cholesterol and triglyceride were increased at the points of 2 and 5 years after operation. The margin of increase of total cholesterol was higher in the patients without endocrine therapy compared to them with endocrine therapy, however there were no changes in the level of triglyceride regardless of endocrine therapy. There were also no significant changes in total cholesterol and triglyceride levels between chemotherapy, radiotherapy and endocrine therapy. 10 year-risk score of ischemic heart disease was increased by 0.44%p in the final observation compared to that of a baseline.

유방암 환자에서 항암 치료가 심혈관질환의 위험에 미치는 영향을 파악하고자 2003년 1월부터 2006년 12월까지 1개 대학병원 유방암센터에서 유방암으로 진단 후 수술을 받은 환자 432명을 대상으로 혈청지질과 10년 내 허혈성 심질환 발생예측위험도의 변화를 보조적 항암 치료와 연관하여 조사하였다. 연구결과 총콜레스테롤과 중성지방은 수술 후 2년 및 5년 측정 시점에서 증가했으며 총콜레스테롤은 내분비요법 비시행군이 시행군보다 2년 및 5년경과 후 증가폭이 컸고 중성지방은 내분비요법 치료 유무에 따라 차이가 없었다. 항암 치료 방법에 따른 총콜레스테롤과 중성지방의 변화는 차이가 없었다. 10년 내 허혈성 심질환 발생예측위험도는 기저치보다 치료 5년 후에 0.44%p 위험도가 증가하였다. 유방암 수술 후 항암화학요법, 방사선 및 내분비요법 치료 시 심혈관질환 위험은 심각한 부작용을 발현하고 있지 않은 것으로 나타났으나 내분비요법 약물사용 유무에 의한 혈청 지질 성분 변화에 대해 정기적인 관련 검사 시행되어야 하며, 운동과 영양 관리 등의 다각적인 고려가 이루어져야 할 것이다.

Keywords

References

  1. World Health Organization, "World Cancer Report 2008", pp. 212-213, 2010.
  2. Korean Breast Cancer Society, "2006-2008 Breast cancer facts & figures", pp. 2-14, 2008.
  3. National Cancer Center, "Cancer facts & figures", pp. 8, 2012.
  4. A. Jemal, R. Siegel, E. Ward, et al, "Cancer statistics, 2006" CA: Cancer Journal for Clinicians, Vol, 56(2), pp. 106-130, 2006. DOI: http://dx.doi.org/10.3322/canjclin.56.2.106
  5. A. Howell, J. Cuzick, M. Baum, et al, "Results of the ATAC (Arimidex, Tamoxifen, Alone or Combination) trial after completion of 5years' adjuvant treatment for breast cancer", Lancet, Vol, 365(9453), pp. 60-62, 2005. DOI: http://dx.doi.org/10.1016/S0140-6736(04)17666-6
  6. National Institute of Health. "Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults final report", Circulation, Vol, 17(24), pp. 3145-3421, 2002.
  7. D. N. Lloyd-Jones, A. R. Dyer, R. Wang, et al. "Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death(Chicago Heart Association Detection Project in Industry)", American Journal of Cardiology, Vol, 99(4), pp. 535-540, 2007. DOI: http://dx.doi.org/10.1016/j.amjcard.2006.09.099
  8. D. Steinberg, J. L. Witztum, "Lipoproteins and atherogenesis; Current concepts:, The Journal of the American Medical Association, Vol, 264(23), pp. 3047-3052, 1990. DOI: http://dx.doi.org/10.1001/jama.264.23.3047
  9. W. B. Kannel, W. P. Castelli, T. Gordon, et al. "Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study", Ann Intern Med, 74(1), pp. 1-12, 1971. DOI: http://dx.doi.org/10.7326/0003-4819-74-1-1
  10. R. J. Glynn, G. J. L'Italien, H. D. Sesson, et al, "Development of predictive models for longterm cardiovascular risk associated with systolic and diastolic blood pressure", Hypertension, Vol, 39(1), pp. 105-110, 2002. DOI: http://dx.doi.org/10.1161/hy1201.097199
  11. K. M. Anderson, P. M. Odell, P. W. F. Wilson, et al, "Cardiovascular disease risk profiles", American Heart Journal, Vol, 121, pp. 293-298, 1990. DOI: http://dx.doi.org/10.1016/0002-8703(91)90861-B
  12. W. B. Kannel, D. McGee, T. Gordon, "A general cardiovascular risk profile: The Framingham Study", The American Journal of Cardiology, Vol, 38(1), pp. 46-51, 1976. DOI: http://dx.doi.org/10.1016/0002-9149(76)90061-8
  13. American Joint Committee on Cancer(AJCC), "Cancer staging manual. Sixth ed", Philadelphia(PA), Lippincott Raven Publishers, 2002.
  14. National Institute of Health, "The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure", NIH Publication No. 03-5233, 2003.
  15. S. H. Jee, J. W. Song, H. K. Cho, et al. Development of the individualized health risk appraisal model of ischemic heart disease risk in Korea", Journal of Korean Lipid and Atherosclerosis, Vol, 14(2), pp. 153-168, 2004.
  16. L. Mosca, H. Mochari, A. Christina, et al. "National study of women's awareness, preventive action, and barriers to cardiovascular health". Circulation, Vol, 113(4), pp. 525-534, 2006. DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.105. 588103
  17. Koran Society of Lipidology and Atherosclerosis. "Dyslipidemia treatment guideline, 2nd edition", pp. 6, 2009.
  18. S. Moorjani, A. Dupont, F. Labrie, et al. "Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide", The Journal of Clinical Endocrinology and Metabolism, Vol, 66(2), pp. 314-322, 1988. DOI: http://dx.doi.org/10.1210/jcem-66-2-314
  19. E. J. Schaefer, D. M. Foster, L. A. Zech, et al. "The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females", The Journal of Clinical Endocrinology and Metabolism, Vol, 57(2), pp. 262-267, 1983. DOI: http://dx.doi.org/10.1210/jcem-57-2-262
  20. H. J. Milionis, E. N. Liberopoulos, M. S. Elisaf, "Tamoxifen-induced hypertriglyceridemia in association with diabetes mellitus", Diabetes and Metabolism, Vol, 27, pp. 160-163, 2001.
  21. M. Elisaf, E. Bairaktari, N. Pavlidis, "The influence of tamoxifen on serum triglycerides", Breast, Vol, 9(4), pp. 238, 2000. DOI: http://dx.doi.org/10.1054/brst.1999.0129
  22. Y. Hozumi, M. Kawano, T. Saito, et al. "Effect of tamoxifen on serum lipid metabolism", The Journal of Clinical Endocrinology and Metabolism, Vol, 83(5), pp. 1633-163, 1998. DOI: http://dx.doi.org/10.1210/jc.83.5.1633
  23. S. Lewis, "Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?", American Heart Journal, Vol, 153(2), pp. 182-188, 2007. DOI: http://dx.doi.org/10.1016/j.ahj.2006.10.034
  24. T. D. Filippatos, E. N. Liberopoulos, N. Pavlidis, et al. "Effects of hormonal treatment on lipis in patients with cancer". Cancer Treatment Reviews, Vol, 35(2), pp. 175-84, 2009. DOI: http://dx.doi.org/10.1016/j.ctrv.2008.09.007
  25. T. Tominaga, I. Kimijima,, M, Kimura, et al. "Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer : Interim results from a Japanese Phase III trial", Japan Journal of Clinical Oncology, Vol, 40(7), pp. 627-633, 2010. DOI: http://dx.doi.org/10.1093/jjco/hyq021